InSilico Medicine Cayman TopCo (HKG:3696)

Market Cap	23.80B
Revenue (ttm)	437.73M -34.5%
Net Income	-2.74B
EPS	-34.87
Shares Out	572.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,655,102
Open	46.50
Previous Close	46.32
Day's Range	40.50 - 47.44
52-Week Range	29.98 - 80.90
Beta	n/a
Analysts	Strong Buy
Price Target	77.26 (+85.81%)
Earnings Date	Mar 30, 2026

About HKG:3696

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, softwar...

• Industry: Software - Infrastructure
• Sector: Technology
• Founded: 2014
• Employees: 317
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3696

Financial Performance

In 2025, HKG:3696's revenue was $56.24 million, a decrease of -34.48% compared to the previous year's $85.83 million. Losses were -$352.32 million, 1960.8% more than in 2024.

Financial numbers in USD